Please login to the form below

Not currently logged in
Email:
Password:

Bayer appoints senior vice president for consumer health unit

Brenda Raphael joins from Pfizer, where she was general manager

Brenda RaphaelBayer has appointed Brenda Raphael as its new senior vice president and general manager of its therapeutic business unit of consumer health operations in North America.

She has previously served Pfizer as its general manager for US brands and her expertise lies in delivering financial gains to businesses and drive insight-led multi channel marketing to consumers.

Prior to this, she has held senior positions at the Coca-Cola Company and Procter & Gamble.

Natalie Bartner, president of North America consumer health division, Bayer, said: “Brenda has more than 20 years of experience in leading successful billion-dollar, consumer-focused brands.

“Her strengths in understanding customers, marketing and innovation will lead the therapeutics business unit to continue developing self-care solutions that help people live healthier lives.”

Raphael will report to Natalie Bartner and she will be based in New Jersey, US.

30th October 2017

From: Sales

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Oncosec

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...

Latest intelligence

EU health fund
An EU emergency health fund to limit the impact of future crises
Leading finance experts propose an Emergency Health Financing Facility to limit the impact of future crises on the EU...
Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...

Infographics